We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
Read MoreHide Full Article
Celldex Therapeutics, Inc. (CLDX - Free Report) reported third-quarter 2016 loss of 29 cents per share, narrower than both the Zacks Consensus Estimate and the year-ago loss of 32 cents.
Total revenue in the third quarter of 2016 surged 120% year over year to $2.2 million, beating the Zacks Consensus Estimate of $1.1 million. Revenues were generated mainly under the clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) , and the research and development agreement with Rockefeller University.
Research and development expenses inched up 1.2% from the year-ago period to $25 million, reflecting higher contract manufacturing costs and personnel costs including higher stock-based compensation expense. On the other hand, general and administrative spend declined 17.6% to $7 million, due to lower commercial planning costs.
Earlier this month, Celldex inked definitive agreement to acquire Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company. The transaction is expected to be completed by 2016 end. Following the transaction, Celldex will acquire the rights to two candidates in Kolltan’s pipeline – KTN0158 (phase I) and KTN3379 (phase Ib). Celldex will also acquire Kolltan’s multi-faceted TAM program.
Meanwhile, Celldex is conducting a phase IIb study (METRIC) on glembatumumab vedotin, its most advanced pipeline candidate, in patients with metastatic triple-negative breast cancers that overexpress gpNMB. The candidate is also being evaluated in several other studies.
Meanwhile, the company is evaluating varlilumab in combination with Bristol-Myers’ Opdivo in a study that includes cohorts in advanced non-small cell lung cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma.
In addition, varlilumab is being evaluated in combination with Roche’s (RHHBY - Free Report) Tecentriq (atezolizumab) in a phase I/II study for multiple solid tumors. Varlilumab is also in several other combination studies.
Celldex expects that cash, cash equivalents and marketable securities plus anticipated proceeds from future sales of its common stock under the agreement with Cantor to be enough to fund working capital requirements and planned operations, including the integration of Kolltan Pharmaceuticals, through 2018.
Celldex currently carries a Zacks Rank #3 (Hold). Infinity Pharmaceuticals, Inc. is a better-ranked stock in the healthcare sector with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Infinity’s loss estimates narrowed from $3.84 to $3.79 for 2016. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67.62%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
Celldex Therapeutics, Inc. (CLDX - Free Report) reported third-quarter 2016 loss of 29 cents per share, narrower than both the Zacks Consensus Estimate and the year-ago loss of 32 cents.
Total revenue in the third quarter of 2016 surged 120% year over year to $2.2 million, beating the Zacks Consensus Estimate of $1.1 million. Revenues were generated mainly under the clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) , and the research and development agreement with Rockefeller University.
Research and development expenses inched up 1.2% from the year-ago period to $25 million, reflecting higher contract manufacturing costs and personnel costs including higher stock-based compensation expense. On the other hand, general and administrative spend declined 17.6% to $7 million, due to lower commercial planning costs.
Earlier this month, Celldex inked definitive agreement to acquire Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company. The transaction is expected to be completed by 2016 end. Following the transaction, Celldex will acquire the rights to two candidates in Kolltan’s pipeline – KTN0158 (phase I) and KTN3379 (phase Ib). Celldex will also acquire Kolltan’s multi-faceted TAM program.
Meanwhile, Celldex is conducting a phase IIb study (METRIC) on glembatumumab vedotin, its most advanced pipeline candidate, in patients with metastatic triple-negative breast cancers that overexpress gpNMB. The candidate is also being evaluated in several other studies.
Meanwhile, the company is evaluating varlilumab in combination with Bristol-Myers’ Opdivo in a study that includes cohorts in advanced non-small cell lung cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma.
In addition, varlilumab is being evaluated in combination with Roche’s (RHHBY - Free Report) Tecentriq (atezolizumab) in a phase I/II study for multiple solid tumors. Varlilumab is also in several other combination studies.
Celldex expects that cash, cash equivalents and marketable securities plus anticipated proceeds from future sales of its common stock under the agreement with Cantor to be enough to fund working capital requirements and planned operations, including the integration of Kolltan Pharmaceuticals, through 2018.
CELLDEX THERAPT Price, Consensus and EPS Surprise
CELLDEX THERAPT Price, Consensus and EPS Surprise | CELLDEX THERAPT Quote
Zacks Rank & Key Picks
Celldex currently carries a Zacks Rank #3 (Hold). Infinity Pharmaceuticals, Inc. is a better-ranked stock in the healthcare sector with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Infinity’s loss estimates narrowed from $3.84 to $3.79 for 2016. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67.62%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>